Delving into the Latest Updates on 中国医学科学院阜外心血管病医院 with Synapse

概览

排名前五的药物类型	数量

小分子化药	1
其他体内诊断药物	1

排名前五的靶点	数量

β2-adrenergic receptor(β2-肾上腺素能受体)	1

关联

1

项与中国医学科学院阜外心血管病医院相关的药物

Higenamine Hydrochloride

盐酸去甲乌药碱

靶点

β2-adrenergic receptor

作用机制

β2-adrenergic receptor激动剂

在研机构

珠海润都制药股份有限公司 [+3]

原研机构

珠海润都制药股份有限公司

在研适应症

造影剂 [+1]

非在研适应症-

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期-

1

项与中国医学科学院阜外心血管病医院相关的临床试验

CTR20202612 / Completed临床3期

以腺苷注射液（90mg/30mL）为对照，评价盐酸去甲乌药碱注射液（2ml：2.5mg）用于核素心肌灌注显像诊断冠心病的随机、交叉、多中心的Ⅲb期临床试验

将盐酸去甲乌药碱注射液及腺苷注射液作为心脏负荷药物用于核素心肌灌注显像诊断冠心病的结果，分别与冠状动脉造影（金标准）的结果相比较，计算盐酸去甲乌药碱注射液与腺苷注射液诊断冠心病的敏感性，并基于敏感性评估盐酸去甲乌药碱注射液与腺苷注射液的非劣效关系，最终为药物注册申请提供充分的依据。

开始日期2021-05-10

申办/合作机构

广东华南新药创制中心

[+3]

100 项与中国医学科学院阜外心血管病医院相关的临床结果

登录后查看更多信息

0 项与中国医学科学院阜外心血管病医院相关的专利（医药）

登录后查看更多信息

3

项与中国医学科学院阜外心血管病医院相关的文献（医药）

2024-10-01·Aging Cell

Aging‐associated atrial fibrillation: A comprehensive review focusing on the potential mechanisms

Review

作者: Xue, Cong ; Zhong, Cheng‐Hao ; Li, Jian‐Jun ; Wang, Meng‐Fei ; Hou, Can ; Jia, Fang

AbstractAtrial fibrillation (AF) has been receiving a lot of attention from scientists and clinicians because it is an extremely common clinical condition. Due to its special hemodynamic changes, AF has a high rate of disability and mortality. So far, although AF has some therapeutic means, it is still an incurable disease because of its complex risk factors and pathophysiologic mechanisms, which is a difficult problem for global public health. Age is an important independent risk factor for AF, and the incidence of AF increases with age. To date, there is no comprehensive review on aging‐associated AF. In this review, we systematically discuss the pathophysiologic evidence for aging‐associated AF, and in particular explore the pathophysiologic mechanisms of mitochondrial dysfunction, telomere attrition, cellular senescence, disabled macroautophagy, and gut dysbiosis involved in recent studies with aging‐associated AF. We hope that by exploring the various dimensions of aging‐associated AF, we can better understand the specific relationship between age and AF, which may be crucial for innovative treatments of aging‐associated AF.

2021-05-01·Catheterization and Cardiovascular Interventions4区 · 医学

Nine‐monthangiographic and2‐yearclinical outcomes of theRECOVERYtrial: A randomized study of the biodegradable polymersirolimus‐eluting COMBO dual‐therapystent versus apolymer‐free sirolimus‐elutingstent in Chinese patients

4区 · 医学

Article

作者: Yin, Zhiyong ; Xu, Bo ; Yu, Bo ; Li, Wei ; Lin, Wenhua ; Tao, Ling ; Li, Hui ; Liu, Yin ; Li, Zhanquan

AbstractObjectivesWe evaluated the safety and efficacy of the novel dual‐therapy sirolimus‐eluting and endothelial progenitor cell (EPC) capture COMBO stent.Background(Very) late stent thrombosis (ST) and neo‐atherosclerosis limit the performance of drug‐eluting stents. The capture of EPCs accelerates stent re‐endothelialization, thereby potentially decreasing the risk of restenosis and ST.MethodsIn total, 440 patients with de novo lesions in native coronary arteries were randomized (1:1) to either receive the COMBO stent (n = 220) or Nano polymer‐free sirolimus‐eluting stent (n = 220). The primary endpoint was the 9‐month angiographic in‐segment late lumen loss (LLL). Secondary endpoints included target lesion failure (TLF), a patient‐oriented composite endpoint (PoCE), and ST.ResultsAt 9 months, the COMBO in‐segment LLL (0.29 ± 0.46 mm) was non‐inferior to that of the Nano comparator stent (0.31 ± 0.44 mm;pnon‐inferiority < .0001). Clinical outcomes were also similar between the COMBO and Nano stents, with TLF rates of 9.3% and 7.9% (p= .61) at 12 months, and 9.4% and 8.0% (p= .62) at 24 months, respectively. The PoCE rate was 14.8% and 10.6% (p= .19) at 12 months, and 16.0% and 11.3% (p= .16) at 24 months, respectively. Ischemia‐driven target lesion revascularization rates were 6.0% and 3.7% (p= .26) at 12 months, and 6.2% and 3.8% (p= .26) at 24 months, respectively. No case of ST occurred in either group.ConclusionsThe RECOVERY trial has shown the COMBO stent was effective, meeting the primary non‐inferiority angiographic endpoint, and safe, with an overall low rate of clinical events in both stent groups, including no ST for up to 2 years.

2019-11-01·Heart Rhythm1区 · 医学

2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy

1区 · 医学

Review

作者: Ackerman, Michael J ; Judge, Daniel P ; Marcus, Frank I ; McKenna, William J ; Zareba, Wojciech ; Daubert, James P ; van Tintelen, J Peter ; Calkins, Hugh ; Keegan, Roberto ; Shimizu, Wataru ; Abrams, Dominic J ; Indik, Julia H ; Darrieux, Francisco C C ; Towbin, Jeffrey A ; de Chillou, Christian ; Sanatani, Shubhayan ; Mestroni, Luisa ; John, Roy M ; Link, Mark S ; Estes, N A Mark ; Hua, Wei ; McLeod, Christopher J ; Ingles, Jodie ; Wilde, Arthur A M ; Saffitz, Jeffrey E ; Krahn, Andrew D ; Priori, Silvia G ; DePasquale, Eugene C ; Desai, Milind Y ; James, Cynthia A

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right/left ventricular cardiomyopathy, cardiac amyloidosis, sarcoidosis, Chagas disease, and left ventricular noncompaction. The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. This expert consensus statement provides the clinician with guidance on evaluation and management of ACM and includes clinically relevant information on genetics and disease mechanisms. PICO questions were utilized to evaluate contemporary evidence and provide clinical guidance related to exercise in arrhythmogenic right ventricular cardiomyopathy. Recommendations were developed and approved by an expert writing group, after a systematic literature search with evidence tables, and discussion of their own clinical experience, to present the current knowledge in the field. Each recommendation is presented using the Class of Recommendation and Level of Evidence system formulated by the American College of Cardiology and the American Heart Association and is accompanied by references and explanatory text to provide essential context. The ongoing recognition of the genetic basis of ACM provides the opportunity to examine the diverse triggers and potential common pathway for the development of disease and arrhythmia.

100 项与中国医学科学院阜外心血管病医院相关的药物交易

登录后查看更多信息

100 项与中国医学科学院阜外心血管病医院相关的转化医学

登录后查看更多信息